CD8A and neoplasm: examined the influence of Siglec-15 on tumor immunity employing B16-GMCSF (PD-1-insensitive) and GL261 (PD-1-sensitive) mouse models and indicated that: First, S15KO mice exhibited slower lump development and a considerable increase in the population of CD8+ T lymphocytes and NK cells in the B16-GMCSF model.